ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer and the Drugs for Neglected Diseases initiative are joining to advance the development of cures for human African trypanosomiasis, visceral leishmaniasis, and Chagas disease, which afflict people in the developing world. Under the agreement, scientists in institutions affiliated with DNDi will test at least 150,000 compounds in Pfizer’s library of novel chemical entities against the parasites that cause the three diseases. According to DNDi, Pfizer’s compound library has never been explored for treatments for these diseases.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter